Use these tools to help track your symptoms and how you're doing with AMITIZA, and share the results with your doctor to get the most out of your next appointment.
Learn more about chronic constipation from these organizations to get a more thorough understanding of the condition.
The Digestive Disease National Coalition (DDNC) is an advocacy organization made up of major national voluntary and professional societies that deal with digestive diseases. The DDNC focuses on improving public policy related to digestive diseases and increasing public awareness with respect to diseases of the digestive system.
The Gastro-Intestinal Research Foundation (GIRF) is a not-for-profit organization dedicated to raising funds for clinical and laboratory research in digestive diseases in the Gastroenterology Section at the University of Chicago Medical Center.
The International Foundation for Functional Gastrointestinal Disorders (IFFGD) Inc. is a nonprofit education and research organization dedicated to informing, assisting, and supporting people affected by gastrointestinal disorders. Founded in 1991, the IFFGD works with patients, families, physicians, nurses, practitioners, investigators, regulators, employers, and others to improve digestive health in adults and children.
The National Digestive Diseases Information Clearinghouse (NDDIC) is an information spreading service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
The NIDDK is part of the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services.
NDDIC was established in 1980 to increase knowledge and understanding about digestive diseases among people with these conditions and their families, health care professionals, and the general public. To carry out this mission, NDDIC works closely with a coordinating panel of representatives from Federal agencies, voluntary organizations on the national level, and professional groups to identify and respond to informational needs about digestive diseases.
Sharing your history with chronic constipation helps your doctor find the treatment plan that is right for you. The Doctor Discussion Guide can help make the conversation more productive.
Find out what to expect when taking AMITIZA.
AMITIZA is for CIC in adults, OIC in adults with chronic, non-cancer pain, and IBS-C in women ≥ 18 years. Effectiveness in patients taking methadone has not been established.
AMITIZA (lubiprostone) is not for everyone. If you know or suspect you have a bowel blockage, do not take AMITIZA. If you are unsure, your healthcare provider (HCP) should evaluate your condition before starting AMITIZA. You should not take AMITIZA if you have severe diarrhea.
Some patients taking AMITIZA may experience nausea or diarrhea. If nausea occurs, take AMITIZA with food and water, if it becomes severe, tell your HCP. If your diarrhea becomes severe, stop taking AMITIZA and tell your HCP.
Within an hour of taking AMITIZA, a sensation of chest tightness and shortness of breath may occur. These symptoms usually go away within three hours, but may recur with repeated use. Tell your HCP if you experience these symptoms.
The most common side effects of taking AMITIZA (24 mcg) twice daily are nausea, diarrhea, headache, abdominal pain, abdominal distension, and gas for patients treated for CIC; nausea and diarrhea for patients treated for Opioid-Induced Constipation. The most common side effects of taking AMITIZA (8 mcg) twice daily for IBS-C are nausea, diarrhea, and abdominal pain. These are not all the side effects associated with AMITIZA.
Tell your HCP if you are taking a diphenylheptane opioid (e.g. methadone).
AMITIZA has not been studied in pregnant women. Based on animal studies, AMITIZA may cause fetal harm. AMITIZA should only be used during pregnancy if the potential benefits justify the potential risk to the fetus. If you are pregnant or become pregnant while being treated with AMITIZA, talk to your HCP to evaluate the risks to the fetus. Tell your HCP if you are nursing and monitor infants for diarrhea.
Tell your HCP if you have liver problems.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
AMITIZA (lubiprostone) 24 mcg capsules twice daily is approved to treat Chronic Idiopathic Constipation (CIC) in adults. “Idiopathic” means the cause of the constipation is unknown and not due to an underlying illness or medication. AMITIZA 24 mcg twice daily is also approved to treat constipation caused by opioids (OIC), a type of prescription pain medicine, in adults with chronic, non-cancer pain. The effectiveness of AMITIZA has not been established if you are taking a diphenylheptane opioid (e.g., methadone). AMITIZA 8 mcg capsules twice daily is approved to treat Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years of age and older.
Please click here for complete Prescribing Information.
You are about to leave this website and enter a website operated by an independent third party.
The links to third-party websites contained on this website are provided solely for your convenience. Takeda does not control the content contained on any third-party website linked from this website. Your activities on those websites will be governed by the policies and practices of those third parties.
Please select "Continue" if you wish to be taken to this third-party website.
This offer cannot be used if you are a beneficiary of, or any part of your prescription is covered by:
You must meet Eligibility Requirements. You agree to report your use of this offer to any Third Party that reimburses you or pays for any part of the prescription price. Use of this offer is confirmation that you are permitted, under the terms and conditions of the health benefit plan(s) covering your prescriptions, to take advantage of co-pay coverage programs. You additionally agree that you will not submit the cost of any portion of the product dispensed pursuant to this offer to a federal or state healthcare program for purposes of counting it toward your out-of-pocket expenses. This savings card covers out-of-pocket expenses up to a maximum benefit of $75 for a 30-day prescription or up to $225 for a 90-day prescription. For mail order prescriptions, a mail-in rebate form is available at www.patientrebateonline.com or by calling 1-866-279-8995. This coupon is not valid with any other program, discount, or incentive involving AMITIZA (lubiprostone). Offer expires 03/31/2017. This offer may be rescinded, revoked, or amended without notice. No reproductions. This offer is void where prohibited by law, taxed, or restricted. Limit one offer per purchase. Cash value of 1/100 of 1¢. For questions about this offer, call the Customer Service Center at
We are unable to complete your web registration. Please contact 1-866-279-8995 to activate a Savings Card.